News Column

Investigators at Shanghai Jiao-Tong University Report Findings in Cancer Gene Therapy (Tumor suppressor miR-24 restrains gastric cancer progression...

August 4, 2014



Investigators at Shanghai Jiao-Tong University Report Findings in Cancer Gene Therapy (Tumor suppressor miR-24 restrains gastric cancer progression by downregulating RegIV)

By a News Reporter-Staff News Editor at Cancer Gene Therapy Week -- Researchers detail new data in Biotechnology. According to news reporting originating from Shanghai, People's Republic of China, by NewsRx correspondents, research stated, "MicroRNAs are small noncoding RNAs that modulate a variety of cellular processes by regulating multiple targets, which can promote or inhibit the development of malignant behaviors. Accumulating evidence suggests miR-24 plays important roles in human carcinogenesis."

Our news editors obtained a quote from the research from Shanghai Jiao-Tong University, "However, its precise biological role remains largely elusive. This study examined the role of miR-24 in gastric cancer (GC). The expression of miR-24 in GC tissues compared with matched non-tumor tissues and GC cells was detected by qRT-PCR. Synthetic short single or double stranded RNA oligonucleotides and lentiviral vectors were used to regulate miR-24 expression in GC cells to investigate its function in vitro and in vivo. miR-24 was significantly downregulated in GC tissues compared with matched non-tumor tissues and was associated with tumor differentiation. Ectopic expression of miR-24 in SGC-7901 GC cells suppressed cell proliferation, migration and invasion in vitro as well as tumorigenicity in vivo by inducing cell cycle arrest in G0/G1 phase and promoting cell apoptosis. Furthermore, we identified RegIV as a target of miR-24 and demonstrated that miR-24 regulated RegIV expression via binding its 3' untranslated region. miR-24 functions as a novel tumor suppressor in GC and the anti-oncogenic activity may involve its inhibition of the target gene RegIV."

According to the news editors, the research concluded: "These findings suggest the possibility for miR-24 as a therapeutic target in GC."

For more information on this research see: Tumor suppressor miR-24 restrains gastric cancer progression by downregulating RegIV. Molecular Cancer, 2014;13():1-13. Molecular Cancer can be contacted at: Biomed Central Ltd, 236 Grays Inn Rd, Floor 6, London WC1X 8HL, England. (BioMed Central - www.biomedcentral.com/; Molecular Cancer - www.molecular-cancer.com)

The news editors report that additional information may be obtained by contacting Y.T. Duan, Shanghai Jiao Tong University, Shanghai Inst Digest Surg, Shanghai Key Lab Gastr NeoplasmsSch Med, Ruijin HospDept Surg, Shanghai 200025, People's Republic of China. Additional authors for this research include L. Hu, B. Liu, B.Q. Yu, J.F. Li, M. Yan, Y.Y. Yu, C. Li, L.P. Su, Z.G. Zhu, M. Xiang, B.Y. Liu and Q.M. Yang (see also Biotechnology).

Keywords for this news article include: Asia, Biotechnology, Shanghai, Oncology, Gastric Cancer, Gastroenterology, Tumor Suppression, Cancer Gene Therapy, People's Republic of China

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC


For more stories covering the world of technology, please see HispanicBusiness' Tech Channel



Source: Cancer Gene Therapy Week


Story Tools






HispanicBusiness.com Facebook Linkedin Twitter RSS Feed Email Alerts & Newsletters